KMT2A Rabbit Polyclonal Antibody

CAT#: TA590838

Rabbit Polyclonal KMT2A/MLL Antibody

Product Images

ELISA: KMT2A / MLL Antibody

• 

  Immunohistochemical staining of human colon shows moderate cytoplasmic and nuclear positivity in glandular cells.This validation was performed by Protein Atlas and the presentation of data is for informational purposes only.

Specifications

Product Data

• Applications: ELISA, IHC
• Recommended Dilution: ELISA: 1:100-1:2000; IHC: 1:150
• Reactivities: Human
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: DNA immunization. This antibody is specific for the Middle Region of the target protein.
• Formulation: 20 mM Potassium Phosphate, 150 mM Sodium Chloride, pH 7.0
• Concentration: 1.2mg/ml
• Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Gene Name: lysine methyltransferase 2A
• Database Link:
  NP_001184033
  Entrez Gene 4297 Human
  UniProt ID Q03164
• Background: The MLL gene encodes a DNA-binding protein that methylates histone H3 (see MIM 601128) lys4 (H3K4) and positively regulates expression of target genes, including multiple HOX genes (see MIM 142980). MLL is a frequent target for recurrent translocations in acute leukemias that may be characterized as acute myeloid leukemia (AML; MIM 601626), acute lymphoblastic leukemia (ALL), or mixed lineage (biphenotypic) leukemia (MLL). Leukemias with translocations involving MLL possess unique clinical and biologic characteristics and are often associated with poor prognosis. MLL rearrangements are found in more than 70% of infant leukemias, whether the immunophenotype is more consistent with ALL or AML6, but are less frequent in leukemias from older children. MLL translocations are also found in approximately 10% of AMLs in adults, as well as in therapy-related leukemias, most often characterized as AML, that develop in patients previously treated with topoisomerase II inhibitors for other malignancies. More than 50 different MLL fusion partners have been identified. Leukemogenic MLL translocations encode MLL fusion proteins that have lost H3K4 methyltransferase activity. A key feature of MLL fusion proteins is their ability to efficiently transform hematopoietic cells into leukemia stem cells (Krivtsov and Armstrong, 2007 [PubMed 17957188]). [supplied by OMIM]
• Synonyms: ALL-1; CXXC7; GAS7; HRX; HTRX1; MLL; MLL1; MLL1A; TET1-MLL; TRX1; WDSTS
• Note: This antibody was generated by SDIX's Genomic Antibody Technology ® (GAT). Learn about GAT

Reference Data

• Protein Families: Druggable Genome